Immunovant Anticipates Key Data Readouts for IMVT-1402 and Batoclimab in 2026, Reports Q3 2025 Financial Results

Immunovant reported Q3 2025 net loss of $110.6 million, a slight improvement from $111.1 million a year earlier. The company's lead asset, IMVT-1402, is being advanced across multiple autoimmune indications, with topline data expected in H2 2026. Batoclimab is in Phase 3 trials for thyroid eye disease, with topline data expected in H1 2026. Immunovant ended the quarter with $994.5 million in cash and cash equivalents.